People: Adamas Pharmaceuticals Inc (ADMS.OQ)
23 Jan 2020
Mr. Neil McFarlane is Chief Executive Officer, Director of the Company. Mr. McFarlane has served as the Chief Operating Officer of Retrophin, Inc., a biopharmaceutical company, from August 2016 until May 2019, in which position he was responsible for global commercial operations, corporate development, patient services, and program and alliance management. Previously, Mr. McFarlane served as the Vice President, Bone business unit for UCB, Inc., a biopharmaceutical company, since 2013, in which role he was responsible for leading the global collaboration with Amgen, and from 2011 to 2013, Mr. McFarlane was the Vice President and General Manager of the US Immunology business unit at UCB, Inc. Prior to his positions at UCB, Mr. McFarlane held positions of increasing responsibility with Genzyme Corporation, a biotechnology company, and Sangstat Medical Corporation prior to its acquisition by Genzyme. Mr. McFarlane served in the United States Army Reserves and received his B.S. and M.S. in Nursing from the University of Florida. Adamas believes Mr. McFarlane’s position as our Chief Executive Officer and his extensive knowledge of the pharmaceutical industry qualifies him to serve on the Board.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|